Publications in collaboration with researchers from University of Orléans (2)

2015

  1. Longterm (52-week) results of a phase III randomized, controlled trial of apremilast in patients with psoriatic arthritis

    Journal of Rheumatology, Vol. 42, Núm. 3, pp. 479-488

2014

  1. Treatment of psoriatic arthritis in a phase 3 randomised, placebo-controlled trial with apremilast, an oral phosphodiesterase 4 inhibitor

    Annals of the Rheumatic Diseases, Vol. 73, Núm. 6, pp. 1020-1026